WO2002094174A2 - Container and method for dispensing transdermal dosage forms - Google Patents
Container and method for dispensing transdermal dosage forms Download PDFInfo
- Publication number
- WO2002094174A2 WO2002094174A2 PCT/US2002/016272 US0216272W WO02094174A2 WO 2002094174 A2 WO2002094174 A2 WO 2002094174A2 US 0216272 W US0216272 W US 0216272W WO 02094174 A2 WO02094174 A2 WO 02094174A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compartment
- dosage form
- container
- transdermal dosage
- unused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/0076—Medicament distribution means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/551—Packaging before or after use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F15/00—Auxiliary appliances for wound dressings; Dispensing containers for dressings or bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/10—Bar codes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/30—Printed labels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2205/00—General identification or selection means
- A61J2205/40—General identification or selection means by shape or form, e.g. by using shape recognition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
Definitions
- the present invention relates to a container and method for dispensing transdermal dosage forms.
- Transdermal dosage forms contain medication to be delivered to a patient.
- the transdermal dosage form e.g., a transdermal patch
- the transdermal dosage form conventionally has a backing layer that is to be removed by the patient thereby revealing the medication and an adhesive so that the form will adhere to the patient's skin.
- the dosage form is placed on the patient, for example, on or near the bicep or on or near the chest, for a prescribed period of time so that the medication can be absorbed through the skin and delivered to the patient.
- the used dosage form will generally contain residua? amounts of the medication.
- some people may illicitly abuse the medication contained in the used or unused dosage form for purposes other than those prescribed by a physician. These people often try to remove the medication from the dosage form, for example, by tearing open the dosage form and digesting the medication orally or by ingesting the medication parentally.
- the container and method includes a container for dispensing transdermal dosage forms comprising a housing that has a first compartment and a second compartment.
- the first compartment has an inlet of a sufficient size to receive a used transdermal dosage form.
- the second compartment has an outlet of a sufficient size to dispense an unused transdermal dosage form.
- a detector of used transdermal dosage forms is placed proximate to the inlet to permit the dispensing of an unused transdermal dosage form from the outlet.
- the container and method includes providing a patient with a first container for receiving used transdermal dosage forms and dispensing unused transdermal dosage forms and rewarding the patient upon the return of the container with used transdermal dosage forms.
- the container and method includes a device for the regulated dispensing of medication including a container having a first compartment and a second compartment.
- a detection device is disposed in relation to the first compartment.
- the first compartment comprises a used dosage form inlet that is unidirectional.
- the detection device determines the presence of a used dosage form at the used dosage form inlet and generates a data signal in response to the recognition of the used dosage form.
- An inlet door is selectively opened and closed in response to the data signal received from the detection device to access the used dosage form inlet.
- the detection device generates a second data signal in response to the used dosage form identified at the used dosage form inlet and disposed in the first compartment.
- the detection device transmitting the second data signal to the second compartment, the second compartment includes an unused dosage form outlet that is unidirectional and dispenses an unused dosage form.
- An outlet door is selectively opened and closed in response to the second data signal received from the detection device to access the unused dosage form outlet.
- the system and method includes dispensing an unused transdermal dosage forms and receiving used transdermal dosage forms.
- a container having a first compartment for receiving used transdermal dosage forms and a second compartment for dispensing unused transdermal dosage forms is provided.
- a used transdermal dosage form proximate to an inlet of the first compartment is scanned to verify that a used transdermal dosage form is being receiving in the first compartment.
- An outlet mechanism of the second compartment receives a communication signal that a used transdermal dosage form has been receiving in the first compartment.
- An unused transdermal dosage form is dispensed from an outlet of the second compartment.
- the present invention also provides a deposit system for transdermal dosage forms that dissuades abuse of used transdermal dosage forms and provides an incentive to return used dosage forms to a dispensing medical professional or other appointed person or agent.
- the method includes (a) providing to a patient a kit comprising a dispenser for used transdermal dosage form(s) and a supply of transdermal dosage forms; and (b) requiring the patient to return the dispenser when the dispenser has been used in order to obtain a new dispenser and a further supply of transdermal dosage forms, wherein the patient is rewarded for returning the used dispenser.
- the dispenser provided to the patient may be a compartmentalized dispenser, such as that described above, or any other disposal and dispensing system for transdermal dosage forms.
- the transdermal dosage form in accordance with one embodiment of the present invention, includes detection indicia, e.g., a bar code or hologram that is readable by a detector contained in a dispensing device, such as that described above.
- detection indicia e.g., a bar code or hologram that is readable by a detector contained in a dispensing device, such as that described above.
- Figure 1 is a perspective view showing a container about to receive a used transdermal dosage form in accordance with the present invention
- Figure 2 shows a schematic of the control mechanism for operating the container of Figure 1;
- Figure 3 shows the container of Figure 1 dispensing an unused dosage form.
- the system includes a container 10 having a first compartment 12 and a second compartment 14.
- First compartment 12 has a used dosage form inlet 16 that is selectively opened and closed by an inlet door 18.
- a detection device 20 is illustrated as being disposed inside compartment 12, but may be disposed external to compartment 12.
- Second compartment 14 has an unused dosage form outlet 22 that is selectively opened and closed by an outlet door 24.
- Inlet 16 is unidirectional and is adapted to receive a used transdermal dosage form 26.
- Inlet door 18 opens when detector 20 detects the presence of a used transdermal dosage form at the inlet.
- the used and unused dosage forms both contain an identification, that is preferably tamperproof.
- the tamperproof identification is read by the detection device to identify the presence of the dosage form. Tamperproof identification may contain a serial number, a patient identification number, a dosage amount, the date and time the dose was dispensed, and/or a refill date.
- the tamperproof identification can be a barcode or a hologram. It can also be an electromagnetic transmitter that emits a signal that the detection device receives or it can transmit a magnetic field that will be detected.
- the tamperproof identification can also have a specific form or shape and only that specific shape (a "key form") will be permitted into the used dosage form inlet.
- the detection device may be a processor to analyze the signal transmitted from the tamperproof identification.
- the detection device can compare the information contained in the signal to a pre-established set of parameters. For example, certain unused dosages, for a particular patient, should be dispensed every 3 days.
- the detection device may read the date and time the used dosage form was dispensed and allow or deny an unused dosage form to be dispensed based on whether 3 days have elapsed.
- the second compartment may contain unused dosage forms containing differing drugs and/or dosage strengths.
- the processor may determine the proper drug and/or dosage strength from the signal and dispense the appropriate unused dosage form. Additionally, the processor may be pre-programmed to dispense a change in dosage strength and/or drugs depending on a pre-programmed prescription regiment based on the patent identification number read from the tamperproof identification.
- the detection device may be disposed inside or outside the first compartment depending on the type of tamperproof identification and location of the device.
- the detection device can first detect the used dosage form and then open the inlet door upon recognition and allow the used dosage form to be inserted into used dosage form inlet.
- the used dosage form inlet may contain the detection device and determine if inlet door should be selectively opened to allow the used dosage form to enter the first compartment.
- Outlet 22 is also unidirectional and is adapted to dispense an unused dosage form 28 only after receiving a signal from the detector that a used dosage form has been received at inlet 16 and stored in first compartment 12.
- the system will not require the receipt of a used dosage form at inlet 16.
- the system may provide a "first dispense only" button 30 on container 10 which will permit the dispensing of an unused dosage form only for the initial dispensing of dosage forms. Thereafter, actuation of button 30 will not result in dispensing of an unused dosage form 28 from compartment 14, and unused dosage forms will be dispensed only if a used dosage form has been received and properly detected in compartment 12.
- the dispensing professional e.g., a pharmacist
- the pharmacist can then activate container 10 to be set to recognize that first dosage form and upon receipt thereof to dispense another unused dosage form so long as all other requirements have been met.
- the user may bring a used transdermal dosage form into contact with or close proximity to detector 20. If the detector recognizes the dosage form as such, the inlet door will open in order for the user to place the used dosage form within the first compartment, and the detector via a CPU 32 will send a signal to the outlet door mechanism 34 in the second compartment, which will open to release an unused transdermal dosage form (see Fig. 2).
- the dosage forms may include a barcode placed on a portion of the dosage form that would become irreparably damaged should the user try to tear open the dosage form or otherwise tamper with the dosage form.
- numerous other tamper proof devices may be used, which device can be detected by detector 20 before communicating a signal to outlet 22, 24 for dispensing another unused dosage form.
- the outlet mechanism 22, 24 may include, as illustrated in the exemplary embodiment shown in Figure 3, a spring biased unused dosage form support plate 32. Plate 32 is supported and biased in the upper direction by springs 34.
- the outlet mechanism may further include a roller 36 that is selectively actuated by CPU 32 to dispense an unused dosage form 28 through outlet 22, as illustrated in Figure 3.
- Both the inlet and outlet may be sized and configured to receive the variety of sizes of transdermal dosage forms that are being used at any given time.
- the inlet and outlet can be sized and configured to receive and dispense only one size of transdermal dosage forms.
- both the first compartment 12 and second compartment 14 are of a sufficient size to house the number of used and unused dosage patches to be stored and dispensed, respectively. Therefore, both the inlet and outlet preferably have dimensions that are suitable for transport of a patch therethrough, e.g.. approximately 15-150 mm diameter for round systems and 15x15 - 150x150 mm for square/rectangular, and the height of these devices should not exceed 10 mm.
- both the inlet and outlet are preferably unidirectional, i.e., the inlet only allows passage of a dosage form into the first compartment, whereas the outlet only allows passage of a dosage form out from the second compartment (and the inlet will not allow a used patch to be taken out of the first compartment through the inlet, nor will the outlet allow a patch to be inserted into the second compartment through the outlet).
- the detector will preferably not initiate a signal that will allow the inlet or outlet doors to open to receive the object and dispense an unused patch.
- container 10 would receive the object, but no signal would be sent to outlet 22, 24, thereby preventing an unused dosage form from being released.
- the detector may be adapted to detect the presence of a transdermal patch by any device necessary as are known to those skilled in the art.
- the patch may be impregnated with a hologram or other signal, such as a bar code, that is detected by the detector.
- a contact switch can be used to detect the insertion of a used transdermal dosage form in the inlet, and/or the detector may include an activating signal that a used transdermal patch has been placed in contact with the inlet.
- a transdermal dosage form is also contemplated that includes a detection indicia, e.g., a hologram or bar code, that may be detected by a detector in a dispenser such as that described above.
- the disposal system may also include one or more inactivating agents in either the first or second compartment.
- an inactivating agent is placed in the first compartment, such that when the user places a used transdermal dosage form in the first compartment, the inactivating agent is released and the agent inactivates any unused medicament contained within the used dosage form.
- the inactivating agent may not, be activated until all used dosage forms have been deposited in the first compartment.
- an inactivating agent may also be included in the second compartment, wherein an opening to the container is in communication with the outlet door and detector. In practice, if the outlet door is tampered with and/or the detector is not activated by placing a used dosage form at the inlet, the inactivating material is released inside the second compartment, thereby inactivating the medicament contained within the unused dosage forms.
- the inactivating agent may be selected from the group consisting of an indelible dye, a biological inactivating agent, a chemical inactivating agent, a denaturing inactivating agent, an electrical inactivating agent, a magnetic inactivating agent, a mechanical inactivating agent, a cross-linking inactivating agent, rat or human mu-opioid receptor, opioid neutralizing antibodies, a narcotic antagonist, irritating or dysphoric agents, or any combination thereof.
- the dosage form may be formulated for virtually any medicament
- the medicament is a controlled substance such as an opioid, benzodiazapene, fentanyl, buprenorphine or etorphine
- the inactivating agent is an opioid or benzodiazepene antagonist or a noxious agent, e.g., an emetic .
- U.S. Patent No. 4,806,341 to Chien discloses possible medicaments and inactivating agents that may be used in the dosage forms used in the present invention.
- Schedule II include, but are not limited to, opium, morphine, and cocaine
- Schedule III substances include, but are not limited to, certain barbiturates and nalorphine
- Schedule IV include, but are not limited to, phenobarbital and certain benzodiazepines; and Schedule V include, but are not limited to, preparations which use opioids.
- an inactivating agent can render the medicament unavailable through inactivation; for example, chemical inactivation or alteration of the receptor binding site of the medicament; electrical inactivation or alteration of the receptor binding site of the medicament; magnetic inactivation or alteration of the receptor binding site of the medicament; mechanical inactivation or alteration of the receptor binding site of the medicament; biounavailability; physical unavailability; loss of appeal of the medicament to the abuser, such as for example, an inactivating agent which creates an intolerably bad taste or an intolerable reaction such as extreme nausea or the like; or something similar thereto.
- One or more inactivating agent(s) may be used.
- the inactivating agent could be a chemical or denaturing agent that would alter residual opioid molecules in the dosage form and make them inactive.
- the inactivating agent could be an opioid receptor that would bind the residual opioid into an insoluble ligand-receptor complex.
- the inactivating agent could also be an opioid receptor antagonist, preferably with greater specificity and/or affinity for the receptor than the opioid, which would be isolated or delivered with the residual opioid upon misuse and compete with the residual opioid for the opioid receptor, thereby defeating the purpose of misusing the opioid. This would render the residual opioid useless in vivo.
- the inactivating agent could also physically sequester the medicament such as, for example, in an impermeable microsphere or in a permanently bound matrix.
- the inactivating agent could be a non-opioid with distressing or dysphoric properties if absorbed that made abuse unappealing.
- the dosage form may also contain a detection material that is also released when the dispenser is tapered with, making it visible to the user that the dosage form has been misused.
- the amount of inactivating agent will depend upon the medicament and the amount of residual medicament that is expected in a particular dosage form. Such amounts can also be determined by those skilled in the art by methods such as establishing a matrix of amounts and effects. However, such amounts should be those amounts effective to achieve the results sought, i.e., inactivation of the residual medicament or the rendering undesirable of a therapeutic drug of abuse.
- Non-limiting examples of medicaments that may be used in the present invention are fentanyl, buprenorphine, etorphine and related opioids of sufficient potency to allow transdermal usage, or any combinations thereof.
- Non-limiting examples of inactivating agents include the rat or human mu-opioid receptor; opioid-neutralizing antibodies; narcotic antagonists such as naloxone, naltrexone and nalmefene; dysphoric or irritating agents such as scopolamine, ketamine, atropine or mustard oils; or "any comoinanons thereof.
- the present invention also provides a deposit system for transdermal dosage forms that dissuades abuse of used transdermal dosage forms and provides an incentive to return used dosage forms to a dispensing medical professional or other appointed person or agent.
- the method includes (a) providing to a patient a kit comprising a dispenser for used transdermal dosage form(s) and a supply of transdermal dosage forms; and (b) requiring the patient to return the dispenser when the dispenser has been used in order to obtain a further supply of transdermal dosage forms, wherein the patient is rewarded for returning the used dispenser.
- the deposit system may comprise providing to a patient a kit comprising a dispenser and a supply of dosage forms at a first price, and when the patient returns the used dispenser, an additional dispenser and supply of dosage forms is provided at a second price, wherein the second price is reduced relative to the first price.
- the reward system may include providing the patient with coupons upon return of the used dispenser, wherein the coupons reduce the cost of subsequent purchases of, e.g., additional dosage forms.
- the container provided to the patient may be a compartmentalized dispenser, such as that described above, or any other disposal system for transdermal dosage forms.
- the container can be made of sturdy construction so that it is tamper proof.
- window(s) may be provided so that the user can determine how many unused dosage forms remain and how many used dosage forms have been deposited.
- a pharmacist can use the window to confirm that the first compartment is actually full of used patches before providing the patient with another container.
- the container can identify the user, alternatively or in addition to the dosage form.
- the container can accept a special encoded tag of the patient, or may even scan the patient directly by a hand/finger/retina, (etc.) scanner to identify the patient.
- the container could include a camera and the detector can perform a visual inspection.
- the container can also monitor how many patches are received and can communicate this information, for example, by the internet, to inform a pharmacist or other monitor that the container is running low.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002590895A JP4302991B2 (en) | 2001-05-22 | 2002-05-22 | Container and device for dispensing transdermal dosage forms |
DK02771869.1T DK1390866T3 (en) | 2001-05-22 | 2002-05-22 | Container and method for delivering transdermal dosage forms |
AT02771869T ATE456097T1 (en) | 2001-05-22 | 2002-05-22 | CONTAINER AND METHOD FOR DISPENSING TRANSDERMAL DOSAGE FORMS |
EP02771869A EP1390866B1 (en) | 2001-05-22 | 2002-05-22 | Container and method for dispensing transdermal dosage forms |
DE60235159T DE60235159D1 (en) | 2001-05-22 | 2002-05-22 | CONTAINER AND METHOD FOR DISPENSING TRANSDERMAL DOSAGE FORMS |
AU2002339382A AU2002339382A1 (en) | 2001-05-22 | 2002-05-22 | Container and method for dispensing transdermal dosage forms |
US10/724,348 US6865444B2 (en) | 2001-05-22 | 2003-11-24 | Container and method for dispensing transdermal dosage forms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29260201P | 2001-05-22 | 2001-05-22 | |
US60/292,602 | 2001-05-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/724,348 Continuation-In-Part US6865444B2 (en) | 2001-05-22 | 2003-11-24 | Container and method for dispensing transdermal dosage forms |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002094174A2 true WO2002094174A2 (en) | 2002-11-28 |
WO2002094174A3 WO2002094174A3 (en) | 2003-07-31 |
Family
ID=23125381
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/016272 WO2002094174A2 (en) | 2001-05-22 | 2002-05-22 | Container and method for dispensing transdermal dosage forms |
Country Status (11)
Country | Link |
---|---|
US (1) | US6865444B2 (en) |
EP (1) | EP1390866B1 (en) |
JP (1) | JP4302991B2 (en) |
AT (1) | ATE456097T1 (en) |
AU (1) | AU2002339382A1 (en) |
CY (1) | CY1109997T1 (en) |
DE (1) | DE60235159D1 (en) |
DK (1) | DK1390866T3 (en) |
ES (1) | ES2340149T3 (en) |
PT (1) | PT1390866E (en) |
WO (1) | WO2002094174A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
US7125561B2 (en) * | 2001-05-22 | 2006-10-24 | Euro-Celtique S.A. | Compartmentalized dosage form |
HUE038446T2 (en) | 2002-09-20 | 2018-10-29 | Alpharma Pharmaceuticals Llc | Sequestering subunit and related compositions and methods |
CL2004000927A1 (en) * | 2003-04-30 | 2005-01-28 | Purdue Pharma Lp | TRANSDERMAL DOSAGE FORM THAT INCLUDES AN ACTIVE AGENT, A NEXT SURFACE AND A DISTAL SURFACE. |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
GB2403711A (en) * | 2003-07-07 | 2005-01-12 | Gw Pharma Ltd | Drug dispenser with controlled access |
KR20080011248A (en) * | 2003-07-25 | 2008-01-31 | 유로-셀띠끄 소시에떼 아노님 | Preoperative treatment of post operative pain |
US7080755B2 (en) * | 2004-09-13 | 2006-07-25 | Michael Handfield | Smart tray for dispensing medicaments |
US20060106491A1 (en) * | 2004-11-02 | 2006-05-18 | Kayner Stephen A | Medication dispensing device |
JP4348741B2 (en) * | 2005-06-27 | 2009-10-21 | 日本電気株式会社 | Optical information recording medium and optical information reproducing apparatus |
WO2007021496A2 (en) * | 2005-08-18 | 2007-02-22 | Walker Digital, Llc | Systems and methods for improved health care compliance |
TWI289059B (en) * | 2006-01-24 | 2007-11-01 | Tsung-Ching Shiu | Prototype machine for in time manufacturing of functional adhesive patch in germ-free room |
US20070196242A1 (en) * | 2006-02-23 | 2007-08-23 | Agamatrix, Inc. | Used test strip storage container |
US20080156821A1 (en) * | 2006-04-25 | 2008-07-03 | Bradley Stuart Galer | Topical preparation dispensers and methods of using the same |
US20070248656A1 (en) * | 2006-04-25 | 2007-10-25 | Galer Bradley S | Topical preparation dispensers and methods of using the same |
EP2484346B1 (en) * | 2006-06-19 | 2017-02-22 | Alpharma Pharmaceuticals LLC | Pharmaceutical compositions |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US20100266645A1 (en) * | 2007-12-17 | 2010-10-21 | Alfred Liang | Pharmaceutical compositions |
US20110161108A1 (en) * | 2009-12-30 | 2011-06-30 | Mckesson Automation Inc. | Systems and methods for detecting diversion in drug dispensing |
US8925727B2 (en) * | 2010-02-01 | 2015-01-06 | Mallinckrodt Llc | Disposable transdermal patch packaging |
US20120090278A1 (en) * | 2010-10-13 | 2012-04-19 | Mallinckrodt Llc | Disposable transdermal patch containment |
US8936030B2 (en) | 2011-03-25 | 2015-01-20 | Katherine Rose Kovarik | Nail polish remover method and device |
US20130095162A1 (en) * | 2011-10-18 | 2013-04-18 | Mary Kathleen Quinn | Adhesive insect repellent strip |
US9953140B2 (en) * | 2013-03-15 | 2018-04-24 | Intent Solutions, Inc. | Systems, methods, and apparatuses for securely dispensing one or more prescribed substances to a securely identified intended user |
US20160214424A1 (en) * | 2015-01-28 | 2016-07-28 | Euris Don Lee Ball | Automatic Writing Implement Dispenser |
BR112017021131A2 (en) | 2015-04-04 | 2018-07-03 | Intent Solutions, Inc. | systems and methods for portable pill dispensers |
CA3087212A1 (en) | 2017-12-27 | 2019-07-04 | Intent Solutions, Inc. | Systems and methods for portable pill dispensers with various dispensing mechanisms |
USD968640S1 (en) | 2018-12-27 | 2022-11-01 | Stryker Corporation | Pharmaceutical waste disposal assembly |
CN110237371B (en) * | 2019-07-09 | 2021-04-20 | 罗健香 | Device for bandaging adhesive bandage for finger wound |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1649435A (en) * | 1924-06-03 | 1927-11-15 | William G Woods | Dispenser |
US1827354A (en) * | 1929-04-03 | 1931-10-13 | Cooper Tea Packet Company | Packet-package and dispensing apparatus |
US2182615A (en) * | 1938-02-28 | 1939-12-05 | Saks And Company | Container |
DE2144812A1 (en) * | 1971-09-08 | 1973-03-15 | Mueller Scherak Wolf Georg | CONTAINER FOR THE PROTECTED STORAGE OF A STACK OF ABOUT THE SAME SHAPED FLAT OBJECTS |
GB2142905B (en) * | 1983-07-09 | 1986-12-31 | Ciba Geigy Ag | Sachet dispenser |
DE3921674C1 (en) * | 1989-07-01 | 1990-10-31 | Ralston Energy Systems Deutschland Gmbh, 4006 Erkrath, De | |
US5271940A (en) * | 1989-09-14 | 1993-12-21 | Cygnus Therapeutic Systems | Transdermal delivery device having delayed onset |
US5507277A (en) * | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5694919A (en) * | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5928194A (en) * | 1997-04-07 | 1999-07-27 | Maget; Henri J. R. | Self-contained liquid microdispenser |
-
2002
- 2002-05-22 PT PT02771869T patent/PT1390866E/en unknown
- 2002-05-22 AT AT02771869T patent/ATE456097T1/en active
- 2002-05-22 DE DE60235159T patent/DE60235159D1/en not_active Expired - Lifetime
- 2002-05-22 ES ES02771869T patent/ES2340149T3/en not_active Expired - Lifetime
- 2002-05-22 EP EP02771869A patent/EP1390866B1/en not_active Expired - Lifetime
- 2002-05-22 WO PCT/US2002/016272 patent/WO2002094174A2/en active Application Filing
- 2002-05-22 AU AU2002339382A patent/AU2002339382A1/en not_active Abandoned
- 2002-05-22 DK DK02771869.1T patent/DK1390866T3/en active
- 2002-05-22 JP JP2002590895A patent/JP4302991B2/en not_active Expired - Fee Related
-
2003
- 2003-11-24 US US10/724,348 patent/US6865444B2/en not_active Expired - Lifetime
-
2010
- 2010-04-14 CY CY20101100334T patent/CY1109997T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
Also Published As
Publication number | Publication date |
---|---|
CY1109997T1 (en) | 2014-09-10 |
EP1390866A2 (en) | 2004-02-25 |
JP2004525740A (en) | 2004-08-26 |
US6865444B2 (en) | 2005-03-08 |
US20040122554A1 (en) | 2004-06-24 |
WO2002094174A3 (en) | 2003-07-31 |
ES2340149T3 (en) | 2010-05-31 |
EP1390866B1 (en) | 2010-01-20 |
AU2002339382A1 (en) | 2002-12-03 |
EP1390866A4 (en) | 2005-06-08 |
ATE456097T1 (en) | 2010-02-15 |
JP4302991B2 (en) | 2009-07-29 |
DE60235159D1 (en) | 2010-03-11 |
PT1390866E (en) | 2010-04-26 |
DK1390866T3 (en) | 2010-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1390866B1 (en) | Container and method for dispensing transdermal dosage forms | |
US20080140250A1 (en) | Secure Dispensing System | |
US6851615B2 (en) | Method of individually tracking and identifying a drug delivery device | |
US9492355B2 (en) | Smart medicine container | |
CN103585021B (en) | Medicament storage and dispensing apparatus and comprise the system of this device | |
US20080027579A1 (en) | Dosage limiting medication dispensing method and apparatus | |
EP2113315B1 (en) | Disposal system for transdermal dosage form | |
US8985388B2 (en) | Smart medicine container | |
EP3151906B1 (en) | Drug device configured for wireless communication | |
US7537005B2 (en) | Dose dispensing system and apparatus | |
US5971594A (en) | Medication dispensing system | |
CN101495080B (en) | Drug storage and dispensing devices and systems comprising same | |
CN101730516B (en) | Storage and dispensing devices for adminsistration of oral transmucosal dosage forms | |
US20180039756A1 (en) | Narcotic Prescription Medication Dispenser | |
US20070271001A1 (en) | Method of remotely managaing the distribution of medicine | |
US20100096399A1 (en) | Smart Medicine Container | |
US20100049363A1 (en) | Smart Medicine Container | |
US20060157491A1 (en) | Dispenser with reservoir containing a drug of abuse | |
US11311460B1 (en) | Method and apparatus of secure storage for dispensing of opioids (SSDO) | |
WO2009063490A2 (en) | An interactive multifunctional system for packaged-product authentication and real-time product dispensation information | |
US20190333619A1 (en) | Monitoring System for Drug Distribution | |
US20190216684A1 (en) | HIPPA Compliant Monitoring System For Drug Distribution And Decreasing Drug Diversion | |
US11854680B1 (en) | Narcotics and opioids secure storage and dispensing apparatus and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002771869 Country of ref document: EP Ref document number: 10724348 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002590895 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002771869 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |